Ground-breaking medications such as Ozempic are being used throughout Australia to address obesity. However, as with many pioneering technologies, these weight loss drugs bring with them many complex implications, including delayed policy adaptations, societal shifts, and questions about their long-term safety.
The weight loss and diet industries have long been plagued by conflicting advice and predatory practices. As several related patents expire in the next few years, we face a critical question: Are we prepared for the widespread use of these medications and their potential consequences?
Join Dr Norman Swan and a panel of experts as they look at the current and future use of GLP-1 inhibitor medications in Australia.